This study is an extension of the DISTOL-1 study that was a placebo controlled medication study for digital ulcers. It allows for those participants who have successfully completed the initial DISTOL-1 study an opportunity to use the drug for up to four
|Effective start/end date||3/1/10 → 8/1/14|
- United Therapeutics Corporation
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.